We are live on ! Find out more
STSA

Satsuma Pharmaceuticals, Inc. Common Stock
STSA

Delisted

STSA was delisted on the 7th of June, 2023.

Back to rankings

36 hedge funds and large institutions have $87.7M invested in Satsuma Pharmaceuticals, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 12 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

3% more funds holding

Funds holding: 35 → 36 (+1)

8% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 12

15% less capital invested

Capital invested by funds: $104M → $87.7M (-$16M)

Holders
36
Holders Change
+1
Holders Change %
+2.86%
% of All Funds
0.57%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
11
Reduced
12
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SC
Samlyn Capital
New York
+$4.62M
2
Walleye Capital
Walleye Capital
New York
+$1.18M
3
Barclays
Barclays
United Kingdom
+$912K
4
Ameriprise
Ameriprise
Minnesota
+$227K
5
IC
Ikarian Capital
Texas
+$108K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$4.01M
2
GTC
Ghost Tree Capital
New York
-$1.94M
3
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
-$309K
4
Two Sigma Investments
Two Sigma Investments
New York
-$216K
5
Morgan Stanley
Morgan Stanley
New York
-$191K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$22.5M – – –
CC
2
Commodore Capital
New York
$14.1M – – –
NMC
3
NEA Management Company
Maryland
$11.9M – – –
SC
4
Samlyn Capital
New York
$10.6M +$4.62M +1,025,355 +58%
TGA
5
TPG GP A
Texas
$7.17M – – –
VC
6
Vivo Capital
California
$4.68M – – –
Ameriprise
7
Ameriprise
Minnesota
$2.86M +$227K +50,273 +7%
IC
8
Ikarian Capital
Texas
$2.48M +$108K +24,064 +4%
Vanguard Group
9
Vanguard Group
Pennsylvania
$2.46M -$29.4K -6,514 -1%
GTC
10
Ghost Tree Capital
New York
$1.8M -$1.94M -430,663 -48%
Walleye Capital
11
Walleye Capital
New York
$995K +$1.18M +261,813 New
Dimensional Fund Advisors
12
Dimensional Fund Advisors
Texas
$835K +$77.4K +17,180 +8%
Barclays
13
Barclays
United Kingdom
$769K +$912K +202,478 New
Citadel Advisors
14
Citadel Advisors
Florida
$706K -$4.01M -890,010 -83%
NFGH
15
Nan Fung Group Holdings
Hong Kong
$543K – – –
BlackRock
16
BlackRock
New York
$509K -$77.2K -17,122 -11%
BCM
17
Bridgeway Capital Management
Texas
$446K +$54.1K +12,000 +11%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$404K +$3.98K +884 +0.8%
Susquehanna International Group
19
Susquehanna International Group
Pennsylvania
$311K -$64.3K -14,267 -15%
Russell Investments Group
20
Russell Investments Group
United Kingdom
$263K – – –
Two Sigma Advisers
21
Two Sigma Advisers
New York
$253K -$96.4K -21,400 -24%
BFM
22
Boothbay Fund Management
New York
$246K – – –
Two Sigma Investments
23
Two Sigma Investments
New York
$194K -$216K -47,873 -48%
State Street
24
State Street
Massachusetts
$164K +$32.3K +7,176 +20%
Northern Trust
25
Northern Trust
Illinois
$148K -$2.38K -528 -1%
1
2

STSA Hedge Fund Activity: Q1 2022 in Review

36 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Satsuma Pharmaceuticals, Inc. Common Stock (STSA) for Q1 2022, worth a combined $87.7M — down 15% from $104M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new STSA positions and 3 closed out — a net gain of 1 holder — while 11 added to existing stakes and 12 trimmed.

The largest buyer was Samlyn Capital, adding an estimated $4.62M. The largest seller was Citadel Advisors, cutting an estimated $4.01M.

  • 36 institutional investors held Satsuma Pharmaceuticals, Inc. Common Stock (STSA) as of Q1 2022, up from 35 in Q4 2021.
  • Funds reported $87.7M of Satsuma Pharmaceuticals, Inc. Common Stock stock for Q1 2022, down 15% quarter-over-quarter.
  • 4 funds opened new Satsuma Pharmaceuticals, Inc. Common Stock positions in Q1 2022 and 3 closed out, a net change of +1 holder.
  • The largest Satsuma Pharmaceuticals, Inc. Common Stock buyer in Q1 2022 was Samlyn Capital, an estimated $4.62M added.
  • The largest Satsuma Pharmaceuticals, Inc. Common Stock seller in Q1 2022 was Citadel Advisors, an estimated $4.01M sold.

Based on aggregated 13F filings for Q1 2022.